Trial reportDiabetes, obesity & metabolism2026
First-In-Human Study of Mirogabalin (BM2216) Sustained-Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimTo characterise the pharmacokinetics (PKs) and safety of BM2216 sustained-release (SR) tablets after single-dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple-dose PK of BM2216 SR tablets with mirogabalin besylate tablets to estimate the bioavailability. MATERIALS AND
methodsThis was a single-centre, randomised, open-label, phase I study conducted in healthy adult participants aged 18-45 years old, consisting of three parts: Part 1 (Food effect and single-dose PK comparison): 18 participants were 1:1:1 randomised into three sequences: (1) 16.5 mg BM2216 (fasting 18:00, QD); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next-day 6:00, 7.5 mg/dose); (3) 16.5 mg BM2216 (post-high-fat dinner, QD). A 3-period crossover design with a 72 h washout period; Part 2 (Single-dose proportionality): 32 participants were equally assigned to four groups, receiving BM2216 SR tablets (5.5, 11, 16.5, or 33 mg) 30 min post-standard meal, respectively; Part 3 (Multiple-dose PK comparison): 16 participants were 1:1 randomised into two sequences: (1) BM2216 (post-dinner, 16.5 mg QD, four consecutive days); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next-day 6:00, 7.5 mg/dose, four consecutive days). Crossover was conducted with a 72 h washout period. PK parameters were calculated and compared using non-compartmental analysis.
resultsThe most common adverse events (AEs) were dizziness (15.6%), increased bile acids (12.5%) and vertigo (12.5%). Dizziness appeared in both the 16.5 and 33 mg dose groups, while vertigo was only seen in the 33 mg group, no serious AEs occurred. Single postprandial doses (5.5-33 mg) exhibited linear PKs: T
conclusionsBM2216 SR was safe and shows linear PK (5.5-3 mg single dose). Due to significant food effect and comparable QD exposure to the reference drug, postprandial QD administration is recommended. These data support further efficacy trials in neuropathic pain patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.